OrbiMed’s Supernus Pharmaceuticals SUPN Stock Holding History

OrbiMed’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-580,000	Closed	-$7.01M	–	149
2015 Q1	$7.01M	Hold	580,000	–	–	0.06%	114
2014 Q4	$4.81M	Hold	580,000	–	–	0.05%	111
2014 Q3	$5.04M	Hold	580,000	–	–	0.05%	113
2014 Q2	$6.35M	Hold	580,000	–	–	0.07%	103
2014 Q1	$5.18M	Hold	580,000	–	–	0.06%	117
2013 Q4	$4.37M	Sell	580,000 -59,400	-9%	-$415K	0.06%	100
2013 Q3	$4.69M	Sell	639,400 -1,856,800	-74%	-$12.5M	0.08%	101
2013 Q2	$16.1M	Buy	+2,496,200	New	+$14.7M	0.34%	59

Other funds holding SUPN

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

MRM

Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

ACM

Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KIA

Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return

OrbiMed's SUPN Position: Q2 2015 in Review

OrbiMed sold out of Supernus Pharmaceuticals (SUPN) in Q2 2015, closing a stake of 580,000 shares — an estimated $7.01M sold.

OrbiMed first reported a position in SUPN in Q2 2013 and held it in 8 quarters. The position peaked at $16.1M in Q2 2013. 165 funds tracked by Wall St. Rank hold SUPN as of Q2 2015.

OrbiMed reported no remaining Supernus Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
OrbiMed sold 580,000 Supernus Pharmaceuticals shares in Q2 2015, an estimated $7.01M.
OrbiMed first reported a position in Supernus Pharmaceuticals in Q2 2013 and held it in 8 quarters.
OrbiMed's Supernus Pharmaceuticals position peaked at $16.1M in Q2 2013.
165 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2015.

Based on OrbiMed's 13F filing for Q2 2015, filed 14 Aug 2015.